Varespladib (LY315920)HnsPLA inhibitor,potent and selective CAS# 172732-68-2 |
- CAY10650
Catalog No.:BCC4178
CAS No.:1233706-88-1
- GSK 2830371
Catalog No.:BCC4179
CAS No.:1404456-53-6
- CP-91149
Catalog No.:BCC3757
CAS No.:186392-40-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 172732-68-2 | SDF | Download SDF |
| PubChem ID | 23674730 | Appearance | Powder |
| Formula | C21H20N2O5 | M.Wt | 380.39 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Varespladib | ||
| Solubility | DMSO : ≥ 32 mg/mL (84.12 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | sodium;2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate | ||
| SMILES | CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)[O-])C(=O)C(=O)N.[Na+] | ||
| Standard InChIKey | XZZUHXILQXLTGV-UHFFFAOYSA-M | ||
| Standard InChI | InChI=1S/C21H20N2O5.Na/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13;/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25);/q;+1/p-1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Selective secreted phospholipase A2 (sPLA2) inhibitor (IC50 = 50 - 750 nM for a range of sPLA2 isoforms). Has no effect on cytosolic PLA2 or COX-1 and COX-2 activity. Attenuates sPLA2-induced thromboxane formation in bronchoalveolar lavage (BAL) cells. Also suppresses sPLA2-induced contractions of lung pleural strips ex vivo. Orally available. |
Varespladib (LY315920) Dilution Calculator
Varespladib (LY315920) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6289 mL | 13.1444 mL | 26.2888 mL | 52.5776 mL | 65.722 mL |
| 5 mM | 0.5258 mL | 2.6289 mL | 5.2578 mL | 10.5155 mL | 13.1444 mL |
| 10 mM | 0.2629 mL | 1.3144 mL | 2.6289 mL | 5.2578 mL | 6.5722 mL |
| 50 mM | 0.0526 mL | 0.2629 mL | 0.5258 mL | 1.0516 mL | 1.3144 mL |
| 100 mM | 0.0263 mL | 0.1314 mL | 0.2629 mL | 0.5258 mL | 0.6572 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: 9 ± 1 nM or 7.3 x 10-6 mole fraction for sPLA2 activity
Phospholipases (PLAs) produce rate-limiting precursors in the various types of biologically active lipid biosynthesis. Increased levels of human nonpancreatic secretory phospholipase A2 (hnps-PLA2) have been detected in several pathological conditions. LY315920 was selected for evaluation clinically as an hnps-PLA2 inhibitor.
In vitro: The true potency of LY315920 was defined to be a mole fraction of 1.5 x 10-6 using a deoxycholate/phosphatidylcholine assay. LY315920 was found to be 40-fold less active against human, group IB, pancreatic sPLA2 and was inactive against cytosolic PLA2 and the constitutive and inducible forms of cyclooxygenase. Human sPLA2-induced thromboxane A2 release from isolated guinea pig lung bronchoalveolar lavage cells was inhibited by LY315920 with the IC50 of 0.79 μM [1].
In vivo: The i.v. administration of LY315920, 5 min before the bronchoalveolar lavage cells harvest, led to the inhibition of sPLA2-induced production of TXA2 with an ED50 of 16.1 mg/kg. [2].
Clinical trials: Varespladib methyl, an oral prodrug of LY-315920, effectively reduced LDL-C and inflammatory biomarkers in ACS patients treated with conventional atorvastatin therapy. There were no treatment differences in clinical cardiovascular events [2].
References:
[1] Snyder DW, Bach NJ, Dillard RD, Draheim SE, Carlson DG, Fox N, Roehm NW, Armstrong CT, Chang CH, Hartley LW, Johnson LM, Roman CR, Smith AC, Song M, Fleisch JH. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther. 1999;288(3):1117-24.
[2] Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol. 2010;56(14):1079-88.
- Senkyunolide S
Catalog No.:BCC9145
CAS No.:172723-28-3
- Fmoc-β-Homo-Val-OH
Catalog No.:BCC2626
CAS No.:172695-33-9
- Fosaprepitant
Catalog No.:BCC4281
CAS No.:172673-20-0
- Clemastanin A
Catalog No.:BCC8151
CAS No.:172670-47-2
- Eucalyptone
Catalog No.:BCN1111
CAS No.:172617-99-1
- Murrayamine E
Catalog No.:BCN7908
CAS No.:172617-68-4
- Naringin 4'-glucoside
Catalog No.:BCN8196
CAS No.:17257-21-5
- Senkyunolide R
Catalog No.:BCC9144
CAS No.:172549-37-0
- Eupatarone
Catalog No.:BCN7199
CAS No.:17249-61-5
- 9-Deacetyl-9-benzoyl-10-debenzoyltaxchinin A
Catalog No.:BCN7671
CAS No.:172486-22-5
- 3',4',5',3,5,6,7-Heptamethoxyflavone
Catalog No.:BCN1110
CAS No.:17245-30-6
- Coumurrayin
Catalog No.:BCN1109
CAS No.:17245-25-9
- Mudanpioside C
Catalog No.:BCN2798
CAS No.:172760-03-1
- Isocucurbitacin B
Catalog No.:BCN8101
CAS No.:17278-28-3
- H-Aib-OEt.HCl
Catalog No.:BCC2670
CAS No.:17288-15-2
- PP 1
Catalog No.:BCC3630
CAS No.:172889-26-8
- PP 2 (AG 1879)
Catalog No.:BCC3631
CAS No.:172889-27-9
- LY 272015 hydrochloride
Catalog No.:BCC7558
CAS No.:172895-15-7
- LY 266097 hydrochloride
Catalog No.:BCC7856
CAS No.:172895-39-5
- Isosinensetin
Catalog No.:BCN2919
CAS No.:17290-70-9
- PB 28 dihydrochloride
Catalog No.:BCC7411
CAS No.:172907-03-8
- FICZ
Catalog No.:BCC5513
CAS No.:172922-91-7
- Biorobin
Catalog No.:BCN4691
CAS No.:17297-56-2
- BWX 46
Catalog No.:BCC5865
CAS No.:172997-92-1
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.[Pubmed:27571102]
Toxins (Basel). 2016 Aug 25;8(9). pii: toxins8090248.
Snakebite remains a neglected medical problem of the developing world with up to 125,000 deaths each year despite more than a century of calls to improve snakebite prevention and care. An estimated 75% of fatalities from snakebite occur outside the hospital setting. Because phospholipase A2 (PLA2) activity is an important component of venom toxicity, we sought candidate PLA2 inhibitors by directly testing drugs. Surprisingly, varespladib and its orally bioavailable prodrug, methyl-varespladib showed high-level secretory PLA2 (sPLA2) inhibition at nanomolar and picomolar concentrations against 28 medically important snake venoms from six continents. In vivo proof-of-concept studies with varespladib had striking survival benefit against lethal doses of Micrurus fulvius and Vipera berus venom, and suppressed venom-induced sPLA2 activity in rats challenged with 100% lethal doses of M. fulvius venom. Rapid development and deployment of a broad-spectrum PLA2 inhibitor alone or in combination with other small molecule inhibitors of snake toxins (e.g., metalloproteases) could fill the critical therapeutic gap spanning pre-referral and hospital setting. Lower barriers for clinical testing of safety tested, repurposed small molecule therapeutics are a potentially economical and effective path forward to fill the pre-referral gap in the setting of snakebite.
Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.[Pubmed:18605714]
J Med Chem. 2008 Aug 14;51(15):4708-14.
We report a series of inhibitors of secreted phospholipases A2 (sPLA2s) based on substituted indoles, 6,7-benzoindoles, and indolizines derived from LY315920, a well-known indole-based sPLA2 inhibitor. Using the human group X sPLA2 crystal structure, we prepared a highly potent and selective indole-based inhibitor of this enzyme. Also, we report human and mouse group IIA and IIE specific inhibitors and a substituted 6,7-benzoindole that inhibits nearly all human and mouse sPLA2s in the low nanomolar range.
Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.[Pubmed:10027849]
J Pharmacol Exp Ther. 1999 Mar;288(3):1117-24.
LY315920 is a potent, selective inhibitor of recombinant human, group IIA, nonpancreatic secretory PLA2 (sPLA2). In a chromogenic isolated enzyme assay, LY315920 inhibited sPLA2 activity with an IC50 of 9 +/- 1 nM or 7.3 x 10(-6) mole fraction, which approached the stiochiometric limit of this assay. The true potency of LY315920 was defined using a deoxycholate/phosphatidylcholine assay with a mole fraction of 1.5 x 10(-6). LY315920 was 40-fold less active against human, group IB, pancreatic sPLA2 and was inactive against cytosolic PLA2 and the constitutive and inducible forms of cyclooxygenase. Human sPLA2-induced release of thromboxane A2 (TXA2) from isolated guinea pig lung bronchoalveolar lavage cells was inhibited by LY315920 with an IC50 of 0.79 microM. The release of TXA2 from these cells by N-formyl-methionyl-leucyl-phenylalanine or arachidonic acid was not inhibited. The i.v. administration of LY315920, 5 min before harvesting the bronchoalveolar lavage cells, resulted in the inhibition of sPLA2-induced production of TXA2 with an ED50 of 16.1 mg/kg. Challenge of guinea pig lung pleural strips with sPLA2 produced contractile responses that were suppressed in a concentration-dependent manner by LY315920 with an apparent KB of 83 +/- 14 nM. Contractile responses induced by arachidonic acid were not altered. Intravenous or oral administration of LY315920 to transgenic mice expressing the human sPLA2 protein inhibited serum sPLA2 activity in a dose-related manner over a 4-h time course. LY315920 is a potent and selective sPLA2 inhibitor and represents a new class of anti-inflammatory agent designated SPI. This agent is currently undergoing clinical evaluation and should help to define the role of sPLA2 in various inflammatory disease states.
